Discontinued ProductUnfortunately L-779,450 (Cat. No. 3185) has been withdrawn from sale for commercial reasons.
Potent, ATP-competitive Raf kinase inhibitor (IC50 = 10 nM) that displays > 7, > 30 and > 70-fold selectivity over p38α, GSK3β and Lck respectively. Suppresses DNA synthesis and induces apoptosis in cells that proliferate in response to Raf-1 and A-Raf but not B-Raf.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Preparing Stock Solutions
The following data is based on the product molecular weight 347.8. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.88 mL||14.38 mL||28.75 mL|
|5 mM||0.58 mL||2.88 mL||5.75 mL|
|10 mM||0.29 mL||1.44 mL||2.88 mL|
|50 mM||0.06 mL||0.29 mL||0.58 mL|
References are publications that support the products' biological activity.
White (2003) Small-molecule inhibitors of signal transduction pathways in leukemia therapeutics: how to assess selectivity for malignant signals. Leukemia 17 1759 PMID: 12970775
Shelton et al (2003) Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia 17 1765 PMID: 12970777
Röring et al (2012) Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J. 31 2629 PMID: 22510884
View Related Products by Product Action
Keywords: L-779,450, supplier, Potent, raf, kinases, inhibitors, inhibits, a-raf, raf-1, L779450, Raf, Kinase, Raf, Kinase, Tocris Bioscience
Citations for L-779,450
Citations are publications that use Tocris products.
Currently there are no citations for L-779,450.
Average Rating:(Based on 0 Reviews)